National Institute of Mental Health; Amended Notice of Meeting, 19564-19565 [E9-9857]

Download as PDF 19564 Federal Register / Vol. 74, No. 81 / Wednesday, April 29, 2009 / Notices Background and Brief Description Reducing congenital syphilis is a national objective in the DHHS Report entitled ‘‘Healthy People 2010 (Vol. I and II)’’. Objective 25–9 of the DHHS document states the goal to ‘‘reduce congenital syphilis to 1 new case per 100,000 live births’’. In order to meet this national objective, an effective surveillance system for congenital Report’’ data collection form will be removed because several states have begun to use a 5-digit (rather than 4digit) FIPS code for city, and CDC data systems cannot accommodate the new codes. The congenital syphilis data will continue to be used to develop intervention strategies and to evaluate ongoing control efforts. There is no cost to respondents other than their time. syphilis must be continued to monitor current levels of disease and progress towards the year 2010 objective. The purpose of the revision is to accommodate minor change to the ‘‘Congenital Syphilis (CS) Case Investigation and Report Form’’ (CDC73.126). In the proposed revision, the ‘‘reporting city’’ and ‘‘resident city’’ information blocks in the ‘‘Congenital Syphilis (CS) Case Investigation and ESTIMATE OF ANNUALIZED BURDEN TABLE No. of responses per respondent No. of respondents Average burden per response (in hours) Total burden (in hours) Type of respondents Name of form State and local health departments .. Congenital Syphilis (CS) Case Investigation and Report. 18 11 20/60 66 Total ........................................... ........................................................... 18 ........................ ........................ 66 Dated: April 23, 2009. Maryam I. Daneshvar, Acting Reports Clearance Officer, Centers for Disease Control and Prevention. [FR Doc. E9–9772 Filed 4–28–09; 8:45 am] BILLING CODE 4163–18–P The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry. Dated: April 17, 2009. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. E9–9743 Filed 4–28–09; 8:45 am] DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention BILLING CODE 4163–18–P Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Strengthening National Capacity in Malaria and Other Infectious Disease Operations Research, Funding Opportunity Announcement (FOA) CK09–003 pwalker on PROD1PC71 with NOTICES In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting. Time And Date: 12 p.m.–3 p.m., June 11, 2009 (Closed). Place: Teleconference. Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463. Matters To Be Discussed: The meeting will include the review, discussion, and evaluation of ‘‘Strengthening National Capacity in Malaria and Other Infectious Disease Operations Research, Funding Opportunity Announcement (FOA) CK09– 003.’’ Contact Person For More Information: Wendy Carr, PhD, CDC, 1600 Clifton Road, NE., Mailstop D60, Atlanta, GA 30333, Telephone: (404) 498–2276. VerDate Nov<24>2008 17:48 Apr 28, 2009 Jkt 217001 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel. Date: May 5, 2009. PO 00000 Frm 00080 Fmt 4703 Sfmt 4703 Time: 8 a.m. to 12 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call) Contact Person: William C. Benzing, PhD, Scientific Review Administrator, Scientific Review Branch, Division Of Extramural Research, NINDS/NIH/DHHS/Neuroscience Center, 6001 Executive Boulevard, Suite 3204, MSC 9529, Bethesda, MD 20892, (301) 496–0660, benzingw@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS) Dated: April 23, 2009. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E9–9863 Filed 4–28–09; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Mental Health; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the National Institute of Mental Health Special Emphasis Panel, May 14, 2009, 9 a.m. to May 14, 2009, 5 p.m., Melrose Hotel, 2430 Pennsylvania Ave., NW., Washington, DC 20037 which was published in the Federal Register on April 17, 2009, 74 FR N17874. The meeting will be held on June 2, 2009. The time and meeting location E:\FR\FM\29APN1.SGM 29APN1 Federal Register / Vol. 74, No. 81 / Wednesday, April 29, 2009 / Notices remains the same. The meeting is closed to the public. Dated: April 22, 2009. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E9–9857 Filed 4–28–09; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Mental Health; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. pwalker on PROD1PC71 with NOTICES Name of Committee: National Institute of Mental Health Special Emphasis Panel. SRSP Conflicts. Date: June 11, 2009. Time: 2 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Melrose Hotel, 2430 Pennsylvania Ave., NW., Washington, DC 20037. Contact Person: Marina Broitman, PhD, Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6153, MSC 9608, Bethesda, MD 20892–9608. 301–402–8152. mbroitma@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.242, Mental Health Research Grants; 93.281, Scientist Development Award, Scientist Development Award for Clinicians, and Research Scientist Award; 93.282, Mental Health National Research Service Awards for Research Training, National Institutes of Health, HHS) Dated: April 22, 2009. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E9–9860 Filed 4–28–09; 8:45 am] BILLING CODE 4140–01–P VerDate Nov<24>2008 17:48 Apr 28, 2009 Jkt 217001 19565 Western Pacific are most seriously affected. Before 1970 only nine countries had experienced Dengue National Institutes of Health Hemorrhagic Fever (DHF) epidemics, a number that had increased more than Prospective Grant of Exclusive four-fold by 1995. WHO currently License: Dengue Tetravalent Vaccine estimates there may be 50 million cases Containing a Common 30 Nucleotide Deletion in the 3′-UTR of Dengue Types of dengue infection worldwide every year. 1,2,3, and 4 The methods and compositions of this AGENCY: National Institutes of Health, invention provide a means for Public Health Service, HHS. prevention of dengue infection and ACTION: Notice. dengue hemorrhagic fever (DHF) by immunization with attenuated, SUMMARY: This is notice, in accordance immunogenic viral vaccines against with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National dengue. The vaccine is further described Institutes of Health (NIH), Department in Blaney JE et al., ‘‘Mutations which of Health and Human Services (HHS), is enhance the replication of dengue virus contemplating the grant of a an type 4 and an antigenic chimeric dengue exclusive license to practice the virus type 2/4 vaccine candidate in Vero following invention as embodied in the cells.’’ Vaccine. 2003 Oct 1;21(27– following patent applications: (1) E– 30):4317–27 and Whitehead SS et al., 120–2001/0, Whitehead et al., ‘‘A live, attenuated dengue virus type 1 ‘‘Development of Mutations Useful for vaccine candidate with a 30-nucleotide Attenuating Dengue Viruses and deletion in the 3′ untranslated region is Chimeric Dengue Viruses’’, Brazilian highly attenuated and immunogenic in Patent Application PI0209943.8, filed monkeys.’’ J. Virol. 2003 Jan;77(2):1653– May 22, 2002, (2) E–089–2002/0,1, 7. Whitehead et al., ‘‘Dengue Tetravalent The prospective exclusive license will Vaccine Containing a Common 30 Nucleotide Deletion in the 3′-UTR of be royalty bearing and will comply with Dengue Types 1,2,3, and 4, or Antigenic the terms and conditions of 35 U.S.C. Chimeric Dengue Viruses 1,2,3, and 4’’, 209 and 37 CFR 404.7. The prospective Brazilian Patent Application exclusive license may be granted unless, PI0309631–9, filed April 25, 2003, and within 60 days from the date of this (3) E–139–2006/0, Whitehead et al., published Notice, NIH receives written ‘‘Development of Dengue Vaccine evidence and argument that establishes Components’’, Brazilian Patent that the grant of the license would not Application TBA, filed August 15, 2007 be consistent with the requirements of to Fundacao Butantan, having a place of 35 U.S.C. 209 and 37 CFR 404.7. business in Sao Paulo, Brazil. The The field of use may be limited to live patent rights in this invention have been attenuated vaccines against dengue assigned to the United States of infections in humans. The Licensed America. Territory may be limited to Brazil. DATE: Only written comments and/or Properly filed competing applications application for a license which are for a license filed in response to this received by the NIH Office of notice will be treated as objections to Technology Transfer on or before May 14, 2009 will be considered. the contemplated license. Comments and objections submitted in response to ADDRESSES: Requests for a copy of the patent application, inquiries, comments this notice will not be made available and other materials relating to the for public inspection, and, to the extent contemplated license should be directed permitted by law, will not be released to: Peter Soukas, Office of Technology under the Freedom of Information Act, Transfer, National Institutes of Health, 5 U.S.C. 552. 6011 Executive Boulevard, Suite 325, Dated: April 23, 2009. Rockville, MD 20852–3804; E-mail: ps193c@nih.gov; Telephone: (301) 435– Richard U. Rodriguez, Director, Division of Technology Development 4646; Facsimile: (301) 402–0220. SUPPLEMENTARY INFORMATION: The global and Transfer, Office of Technology Transfer, National Institutes of Health. prevalence of dengue has grown [FR Doc. E9–9853 Filed 4–28–09; 8:45 am] dramatically in recent decades. The BILLING CODE 4140–01–P disease is now endemic in more than 100 countries in Africa, North and South America, the Eastern Mediterranean, Southeast Asia and the Western Pacific. Southeast Asia and the DEPARTMENT OF HEALTH AND HUMAN SERVICES PO 00000 Frm 00081 Fmt 4703 Sfmt 4703 E:\FR\FM\29APN1.SGM 29APN1

Agencies

[Federal Register Volume 74, Number 81 (Wednesday, April 29, 2009)]
[Notices]
[Pages 19564-19565]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-9857]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Mental Health; Amended Notice of Meeting

    Notice is hereby given of a change in the meeting of the National 
Institute of Mental Health Special Emphasis Panel, May 14, 2009, 9 a.m. 
to May 14, 2009, 5 p.m., Melrose Hotel, 2430 Pennsylvania Ave., NW., 
Washington, DC 20037 which was published in the Federal Register on 
April 17, 2009, 74 FR N17874.
    The meeting will be held on June 2, 2009. The time and meeting 
location

[[Page 19565]]

remains the same. The meeting is closed to the public.

    Dated: April 22, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-9857 Filed 4-28-09; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.